Methylene blue has one of the longer clinical track records of any compound currently discussed in biohacking circles, precisely because it has been in clinical use for well over a century. Its regulatory history is more recent and much narrower than that longevity suggests: for most of those decades methylene blue was a marketed but formally unapproved drug, and the first FDA-approved methylene blue product, ProvayBlue, carries an initial U.S. approval date of 2016[1]. Long clinical familiarity and a modern regulatory approval are two different things, and only one of them implies trial evidence.
This article walks through the areas where methylene blue has actual human trial data, distinguishing established clinical use from early-stage or preliminary research.
Key Takeaways
- Methylene blue’s only FDA-approved human indication is treatment of acquired methemoglobinemia[1]. Clinical experience there is extensive, but the approval itself dates to 2016 and rested on retrospective case data rather than a controlled trial.
- Randomized human trials exist for Alzheimer’s disease (tau-targeted formulations, which missed their primary endpoint)[4], for vasoplegia and septic shock (where several small randomized trials were positive)[7][9], and for residual depressive symptoms in bipolar disorder[11].
- No adequately powered randomized controlled trial has established methylene blue as an effective cognitive enhancer or longevity intervention in healthy adults.
- Controlled data in healthy adults is not absent, but it is thin and narrow: a single randomized, double-blind, placebo-controlled study of 26 people, reported in two papers by the same group, measuring a one-hour single-dose effect[2][3].
The Established Clinical Use: Methemoglobinemia
Methylene blue’s FDA approval for acquired methemoglobinemia was granted in 2016 to ProvayBlue[1], and it is worth being precise about what that approval rested on: decades of accumulated clinical use and retrospective case data, not a randomized trial. The compound had been given to patients for generations before any modern approval process was applied to it. In this condition, hemoglobin is oxidized into a form that cannot carry oxygen effectively. Intravenous methylene blue, administered by a physician, acts as an electron donor that helps convert the affected hemoglobin back to its oxygen-carrying form. This remains the most rigorously established human use of the compound and the one with the clearest dosing and safety data.
Alzheimer’s Disease and Tauopathy Trials
Because methylene blue can inhibit tau protein aggregation in laboratory models, several clinical trials have tested methylthioninium-based formulations in people with Alzheimer’s disease and related conditions. The largest of these was a phase 3 trial of LMTM, a stabilized reduced form of methylene blue, in 891 people with mild or moderate Alzheimer’s disease[4]. It is commonly described online as a mixed or dose-dependent result. It was not. The published conclusion is that the prespecified primary analyses "did not show any treatment benefit at either of the doses tested", and the authors state the findings "do not suggest benefit of LMTM as an add-on treatment". A second phase 3 trial of 800 participants reported a more favourable signal for people taking LMTM on its own rather than alongside standard Alzheimer’s drugs. That comparison, however, was explicitly non-randomised, and its own authors called for a properly randomised trial to test it[5]. No methylene blue derivative has received regulatory approval for treating dementia.
Septic Shock and Vasoplegia
In critical care settings, methylene blue has been studied as an adjunct treatment for vasoplegic shock, a state of dangerously low blood pressure resistant to standard vasopressors, sometimes seen in sepsis or after cardiac surgery. This is, somewhat counter-intuitively, the setting with methylene blue’s strongest controlled human outcome data, not the cognitive literature. Several small randomized controlled trials have been run here: a 20-patient pilot in septic shock that reduced vasopressor requirements[6]; a trial in which 56 post-cardiac-surgery vasoplegic patients were randomized to methylene blue or placebo, reporting mortality of 0% versus 21.4% (p = 0.01)[7]; a 100-patient trial of preoperative dosing in high-risk cardiac surgery that reported vasoplegic syndrome in 0% versus 26% (p < 0.001)[8]; and a 91-patient randomized placebo-controlled septic shock trial that shortened time to vasopressor discontinuation (69 h versus 94 h, p < 0.001) with no difference in mortality[9]. Every one of these used intravenous methylene blue, in hospital, in critically ill patients, at doses around 1.5-2 mg/kg. They are evidence about emergency haemodynamic rescue. They say nothing whatsoever about oral supplementation in a healthy person, and should never be cited as if they did.
Depression and Mood-Related Research
Given its MAO-inhibiting properties, methylene blue has been examined in a small number of controlled mood trials, both in bipolar disorder and both as an add-on to existing medication. A two-year double-blind crossover trial in 31 people on lithium found participants significantly less depressed during the year on 300 mg/day than on 15 mg/day, though only 17 completed and the authors themselves flagged doubts about blinding and whether the low dose was really a placebo[10]. A later six-month double-blind crossover trial in 37 people taking lamotrigine compared 195 mg with 15 mg and found improvement in depression and anxiety scores, but no significant effect on cognitive symptoms[11]. Note the design both share: the comparator is a low dose of methylene blue, not an inert placebo, because the compound turns urine blue and cannot be blinded conventionally. Sample sizes are small, both studies were add-on rather than standalone treatment, and none of this research has produced an approved psychiatric indication. Anyone currently on antidepressant medication should treat this research as a reason for caution rather than encouragement, given the serotonin syndrome interaction risk discussed elsewhere on this site.
What’s Missing: Trials in Healthy, Nootropic-Use Populations
The most important gap for anyone considering methylene blue as a cognitive or energy-support compound is not that controlled data in healthy adults is missing altogether. That claim is often repeated and it is not accurate. A randomized, double-blind, placebo-controlled trial in 26 healthy adults aged 22-62 did test a single low oral dose, and reported a 7% increase in correct responses during memory retrieval (P = .01) alongside changes in functional MRI response[2]; a companion paper from the same group reported altered functional connectivity[3]. What is missing is everything that would let you act on that: the finding comes from one small cohort studied by one group, measured about an hour after a single dose, using brain imaging and a laboratory memory task rather than any real-world outcome. There is no adequately powered replication, no independent group, and no trial of repeated dosing over weeks or months in healthy people. Most of the human evidence base comes from patient populations with a diagnosed condition, using doses and delivery routes different from what is typically discussed in biohacking contexts. That does not mean the mechanistic rationale is invalid, but it does mean confident claims of cognitive enhancement in healthy people outrun the current trial evidence.
As an Amazon Associate and affiliate partner, this site earns from qualifying purchases linked in this article. This does not change the price you pay and does not influence the safety information below.
Frequently Asked Questions
Has methylene blue been proven to improve memory or focus in clinical trials?
Not in adequately powered trials. One small randomized, double-blind, placebo-controlled study of 26 healthy adults did report a 7% improvement in memory retrieval one hour after a single low oral dose[2], so it is not true that healthy people have never been studied. But that is a single small cohort from one research group measuring an immediate, laboratory-task effect. It has not been replicated at scale, and the bulk of the human trial literature still involves patients with methemoglobinemia, Alzheimer’s disease or critical illness.
Is methylene blue FDA-approved for anything?
Yes, for treating acquired methemoglobinemia. This is its only approved indication; other uses discussed in research or online are investigational or off-label.
What happened with methylene blue Alzheimer’s trials?
They were negative on their primary endpoint. The phase 3 LMTM trial in 891 people reported that the prespecified primary analyses showed no treatment benefit at either dose tested[4]. A second trial suggested a better result for people taking it as monotherapy, but that comparison was not randomised and its authors asked for a proper randomised trial to confirm it[5]. No formulation has received regulatory approval for treating dementia.
Is methylene blue used in hospitals today?
Yes, primarily intravenously for methemoglobinemia and, in some centers, as an adjunct for vasoplegic shock during or after major surgery, both under direct physician supervision.
Should I trust anecdotal reports over clinical trial data?
Anecdotal reports can be informative for generating hypotheses but should not substitute for controlled trial evidence, particularly for a compound with a narrow therapeutic window and serious drug interaction risks like methylene blue.
References
- ProvayBlue (methylene blue) injection, USP, for intravenous use. FDA prescribing information, NDA 204630. Initial U.S. Approval: 2016. DailyMed label
- Rodriguez P, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology 2016;281(2):516-526. PMID 27351678
- Rodriguez P, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav 2017;11(3):640-648. PMID 26961091
- Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016;388(10062):2873-2884. PMID 27863809
- Wilcock GK, et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J Alzheimers Dis 2018;61(1):435-457. PMID 29154277
- Kirov MY, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001;29(10):1860-7. PMID 11588440
- Levin RL, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77(2):496-9. PMID 14759425
- Ozal E, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005;79(5):1615-9. PMID 15854942
- Ibarra-Estrada M, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care 2023;27(1):110. PMID 36915146
- Naylor GJ, et al. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 1986;21(10):915-20. PMID 3091097
- Alda M, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry 2017;210(1):54-60. PMID 27284082
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.